Valirx (VAL) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Sep 2024 07:00 AM
RNS
Inaphaea Evaluation and Commercial Use Agreement
16 Sep 2024 07:00 AM
RNS
Inaphaea Co-Marketing Agreement
09 Sep 2024 07:00 AM
RNS
Inaphaea Evaluation and Commercial Use Agreement
09 Sep 2024 07:00 AM
RNS
Investor Evening
27 Aug 2024 07:00 AM
RNS
Inaphaea Evaluation and Commercial Use Agreement
12 Aug 2024 07:00 AM
RNS
Directorate Change
25 Jul 2024 07:00 AM
RNS
Directorate Changes
03 Jul 2024 08:51 AM
RNS
Proposed Director Appointment
20 Jun 2024 05:56 PM
RNS
Result of AGM
19 Jun 2024 11:33 AM
RNS
Directorate Change
17 Jun 2024 07:00 AM
RNS
Inaphaea Contract Award
28 May 2024 07:00 AM
RNS
Investor Webinar
20 May 2024 12:00 PM
RNS
Business Update
16 May 2024 07:00 AM
RNS
Further re Final Results
15 May 2024 07:00 AM
RNS
Final Results and Notice of AGM
22 Apr 2024 07:00 AM
RNS
Directorate Changes
21 Mar 2024 07:00 AM
RNS
Evaluation Agreement with Imperial College London
19 Mar 2024 07:00 AM
RNS
Board Re-structuring and update on requisition
04 Mar 2024 05:47 PM
RNS
Shareholder Requisition Notice
04 Mar 2024 07:00 AM
RNS
Proposed Appointment of Non-Executive Director
29 Feb 2024 02:00 PM
RNS
Proposed Appointment of Non-Executive Director
13 Feb 2024 02:20 PM
RNS
Further re Shareholder Requisition Notice
12 Feb 2024 05:33 PM
RNS
Holding(s) in Company
12 Feb 2024 07:00 AM
RNS
Agreement with Dundee Uni and Project Initiation
09 Feb 2024 05:06 PM
RNS
Shareholder Requisition Notice
19 Jan 2024 07:00 AM
RNS
Change of Broker
18 Jan 2024 07:00 AM
RNS
Directorate Change
04 Jan 2024 01:48 PM
RNS
Result of GM, Issue of Equity
19 Dec 2023 06:11 PM
RNS
Result of Retail Offer, Subscription
15 Dec 2023 07:00 AM
RNS
Posting of Circular, Notice of GM and Ops Review
13 Dec 2023 04:56 PM
RNS
Retail Offer
13 Dec 2023 04:49 PM
RNS
Conditional Fundraise, Notice of General Meeting
05 Dec 2023 07:00 AM
RNS
Agreement to License VAL401 to Ambrose Healthcare
10 Nov 2023 07:00 AM
RNS
Evaluation Agreement with StingRay Bio
06 Oct 2023 10:45 AM
RNS
Statement re Share Price Movement
28 Sep 2023 07:00 AM
RNS
Operational Review
24 Aug 2023 07:00 AM
RNS
Half-year Report
14 Aug 2023 07:00 AM
RNS
Collaborative Services Agreement
19 Jul 2023 07:00 AM
RNS
Inaphaea BioLabs secures first external contract
28 Jun 2023 02:15 PM
RNS
Result of AGM
20 Jun 2023 07:00 AM
RNS
Virtual AGM Access
19 Jun 2023 07:00 AM
RNS
Inaphaea BioLabs Operational Update
16 Jun 2023 07:00 AM
RNS
Conclusion of Hokkaido Evaluation Agreement
14 Jun 2023 07:00 AM
RNS
Asset Purchase – Imagen Therapeutics
08 Jun 2023 07:00 AM
RNS
Update on proposed sub-license of VAL201
07 Jun 2023 07:00 AM
RNS
Expanded agreement with University of Barcelona
05 Jun 2023 07:00 AM
RNS
Final Results and Notice of AGM
26 May 2023 07:00 AM
RNS
Notice of Results and Investor Webinar
02 May 2023 02:29 AM
BZW
Valaris Announces Appointment of New ARO Dril...
02 May 2023 02:28 AM
BZW
Valaris Provides Fleet Status Report

ValiRx is a fast-growing drug development company focused on identifying novel science with high potential for successful development into products that improve the lives of patients throughout treatment.

ValiRx listed on AIM in 2004 under the ticker VAL.

UK 100